Navigation Links
Data from Rexahn Pharmaceuticals' Phase I Trial of RX-0201,(Archexin) to Be Presented at the 43rd American Society of Clinical,Oncology Annual Meeting in Chicago

ROCKVILLE, Md.--(BUSINESS WIRE)--May 30, 2007 - Rexahn Pharmaceuticals, Inc. (OTC BB:RXHN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs, today announced that Dr. John Marshall, Principal Investigator of Phase I clinical trial of the Company's lead cancer compound RX-0201 (Archexin), will present results of the clinical study at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 1-5, 2007 at McCormick Place in Chicago, Illinois.

The presentation, entitled, "A Phase I Trial of RX-0201 (AKT anti-sense) in Patients with Advanced Cancer," is scheduled for Sunday, June 3, 2007 at 9am Central Time.

About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals is a biopharmaceutical company leveraging its unique technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn's compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy. For Additional information about Rexahn visit www.rexahn.com.

Contact

Rexahn Pharmaceuticals, Inc.
Amanda Sawney, 240-268-5300 x300


'"/>




Page: 1

Related medicine technology :

1. Faust Pharmaceuticals Phase IIa Results for Parkinsons Disease Presented at International Congress of Parkinsons Disease and Movement Disorders
2. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
3. Aeolus Pharmaceuticals AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation
4. Aeolus Pharmaceuticals AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy
5. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
6. ACADIA Pharmaceuticals Schizophrenia Programs to Be Presented at the 2007 International Congress on Schizophrenia Research
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:8/27/2015)... Aug. 27, 2015  BioElectronics Corporation (OTC Pink: BIEL), the ... three abstracts featuring the use of ActiPatch®, its novel ... th Congress of the European Pain Federation EFIC®, ... September 2015. The Company will also be exhibiting at ... Gianluca Bagnato , department clinical and experimental rheumatology from ...
(Date:8/27/2015)... Aug. 27, 2015   Americord Registry , a ... and placenta tissue banking company, announced today ... e-commerce website. This new website makes the expecting parent,s ... interactive shopping cart and checkout process. Logo ... blood banking websites make this service difficult to purchase ...
(Date:8/27/2015)... 27, 2015  Zimmer Biomet Holdings, Inc. (NYSE and ... that it will be participating in the Goldman Sachs ... Sachs offices in London on ... Founded in 1927 and headquartered in Warsaw, ... in musculoskeletal healthcare.  We design, manufacture and market orthopaedic ...
Breaking Medicine Technology:BioElectronics Selected to Present its Pain Research and Devices at the European Pain Federation Conference 2Cord Blood Bank Revolutionizes Process of Online Cord Blood Banking 2
... Symmetry Medical Inc. (NYSE: SMA ), a leading ... and other medical markets, announced today that it has entered ... November 3, 2010.  The credit facility includes an "accordion feature" ... million. The credit facility has a term of five years. ...
... Nov. 3, 2010 Aethlon Medical, Inc. (OTC ... in developing therapeutic filtration devices to address infectious ... present tomorrow at the at the Singular Research ... Los Angeles. (Photo:   http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b ) ...
Cached Medicine Technology:Symmetry Medical Closes $200 Million Credit Facility 2Symmetry Medical Closes $200 Million Credit Facility 3Aethlon Medical to Present at the Singular Research Fifth Annual 'Best of the Uncovereds Conference' 2Aethlon Medical to Present at the Singular Research Fifth Annual 'Best of the Uncovereds Conference' 3Aethlon Medical to Present at the Singular Research Fifth Annual 'Best of the Uncovereds Conference' 4
(Date:8/27/2015)... ... ... About 10 percent of mothers experienced chronic, persistent depressive ... than 1,800 people, displacing hundreds of thousands and causing widespread damage estimated at ... most people don’t develop persistent depression after a major disaster like that, a ...
(Date:8/27/2015)... ... ... The Naderi Center is proud to announce that its own Dr. Jessica ... fat. The first and only Food and Drug Administration (FDA) approved treatment for ... only Board Certified surgeon in the D.C., Maryland, Virginia area to offer this innovative, ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... its Krames Patient Education content is ICD-10 ready and available to all clients. ... new ICD-10 code sets, which are more targeted and return a more comprehensive ...
(Date:8/27/2015)... ... 2015 , ... Zensah®, the premium athletic compression company, is ... in the Women’s Tennis Association (WTA). Glushko competes in tennis tournaments around the ... a focus on technology and comfort, Zensah® has developed compression gear to help ...
(Date:8/27/2015)... ... ... In addition to its existing Doctor of Philosophy in Leadership and Doctor ... main campus in Reading: Doctor of Nursing Practice. , Alvernia’s Doctor of Nursing ... for the highest level of clinical nursing practice. , “Our vision is to ...
Breaking Medicine News(10 mins):Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 2Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2
... under the Revised National TB Control Programme (RNTCP) aims ... treatment and diagnostic services to all tuberculosis patients. It ... HIV-positive people are more prone to contracting tuberculosis. Hence ... plan to tackle this issue and multi-drug resistant cases. ...
... and minds of various people world over. But now it ... detox products are to be investigated by the British government. ... attention to some of their medical claims. , ,The ... based on investigations by Real Story's Doctors on a Detox ...
... attempting of suicide is high among the children of men ... the University of British Columbia and several other institutions in ... working or had worked at sawmills in British Columbia - ... ,They collected data on the men's history of employment, their ...
... for calming the nervous, can act otherwise leading ... ,Substances like diphenhydramine, which can be ... says Ursula Sellerberg, spokeswoman for the Federal Organization ... ,Diazepam, the main ingredient in valium, can ...
... new studies, researchers claim that more people could be ... cow disease than previously thought after new evidence emerged ... developing. // According to the scientists from Edinburgh a ... to pass through blood transfusions and surgical instruments, can ...
... market in Norwich is a non-referral drop-in-center aimed at people, ... after its fallen apart. // Founded in 1994, the centre ... mental health charity Rethink. The centre will be launching an ... and shallowness, that follows mental illness. ,The place is ...
Cached Medicine News:Health News:India to Implement National Action Plan against TB-HIV 2Health News:Mad Cow Disease – Worst Is Yet To com 2Health News:Bridging People’s lives, Post Upheava 2
... is suspected, every minute counts. ... allows rapid determination of the ... a single whole blood sample. ... within minutes - saving you ...
... Endoscopic cases it is extremely popular to combine ... Light. This combination affords the surgeon optimal ... an uncomfortable pose. The Dual Light System ... System. As such the light can be ...
... offers all the performance of a major surgical ... use in Outpatient Settings, Minor Procedure Rooms, C-Section, ... single lights either side of the OR table ... General OR when combining Flat Screen LCD Monitors ...
A Western Blot Immunassay for the detection of antibodies to primarily anti-myelin associated glycoproteins (anti-MAG) and other glycolipid autoantibodies in human serum....
Medicine Products: